Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Zhishen, Ye"'
Autor:
Ondrej Podlaha, George Wu, Bryan Downie, Raghuraman Ramamurthy, Anuj Gaggar, Mani Subramanian, Zhishen Ye, Zhaoshi Jiang
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0220376 (2019)
Hepatitis B infection is a world-wide public health burden causing serious liver complications. Previous studies suggest that hepatitis B integration into the human genome plays a crucial role in triggering oncogenic process and may also constitutive
Externí odkaz:
https://doaj.org/article/88c92b48a1ba4cd9ab5ca1e561d030e0
Autor:
Zhishen Ye, B Nebiyou Bekele
Publikováno v:
Journal of Biopharmaceutical Statistics. 28:1055-1077
Mixed Effects Models for Repeated Measures (MMRM) is often used in clinical trials with longitudinal data. However, there has not been an in-depth examination available on how investigators can implement interim analysis while also controlling the ov
Autor:
Zhaoshi Jiang, Zhishen Ye, George Wu, Mani Subramanian, Ondrej Podlaha, Anuj Gaggar, Raghuraman Raghuraman Ramamurthy, Bryan R. Downie
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0220376 (2019)
PLoS ONE
PLoS ONE
Hepatitis B infection is a world-wide public health burden causing serious liver complications. Previous studies suggest that hepatitis B integration into the human genome plays a crucial role in triggering oncogenic process and may also constitutive
Autor:
B. Freilich, Stuart K. Roberts, John G. McHutchison, Eric Sicard, Anuj Gaggar, Carla S. Coffin, Wendy Cheng, Zhishen Ye, Kimberly L. Garrison, Kumar Visvanathan, E.J. Gane, G. Mani Subramanian, Yoon Jun Kim, Richard N. Fedorak, Benedetta Massetto, Shyamasundaran Kottilil, Stuart C. Gordon, Young-Suk Lim, Stefan Pflanz
Publikováno v:
Journal of Hepatology. 63:320-328
Background & Aims GS-9620 is an oral agonist of toll-like receptor 7, a pattern-recognition receptor whose activation results in innate and adaptive immune stimulation. We evaluated the safety, pharmacokinetics, and pharmacodynamics of GS-9620 in pat
Autor:
Ondrej Podlaha, Anuj Gaggar, George Y. Wu, Bryan R. Downie, Mani Subramanian, Zhaoshi Jiang, Zhishen Ye, Raghuraman Raghuraman Ramamurthy
Publikováno v:
Journal of Hepatology. 70:e714
Autor:
Neal D. Shore, Gavin Marx, Paul Sieber, Fred Saad, Carsten Goessl, Juan Morote, Stéphane Oudard, Ronaldo Damião, Peter J. Van Veldhuizen, Karim Fizazi, Zhishen Ye, Matthew R. Smith, Roger Dansey, Kurt Miller, Bertrand Tombal
Publikováno v:
Journal of Clinical Oncology. 31:3800-3806
Purpose Denosumab, an anti–RANK ligand monoclonal antibody, significantly increases bone metastasis–free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis in men with nonmetastatic castration-resistant pr
Autor:
Jie Yang, Zhishen Ye
Publikováno v:
Journal of Statistical Planning and Inference. 140:3121-3131
We propose a new method for dimension reduction in regression using the first two inverse moments. We develop corresponding weighted chi-squared tests for the dimension of the regression. The proposed method considers linear combinations of Sliced In
Publikováno v:
Journal of Clinical Epidemiology. 57:21-29
Background and Objective The aim of this study was to develop and apply an automated linkage algorithm to 10 years of California hospitalization discharge abstracts and death records (1990 to 1999), evaluate linkage accuracy, and identify sources of
Autor:
Zhishen Ye, Robert E. Weiss
Publikováno v:
Journal of the American Statistical Association. 98:968-979
Dimension reduction in a regression analysis of response y given a p-dimensional vector of predictors x reduces the dimension of x by replacing it with a lower-dimensional linear combination β′x of the x's without specifying a parametric model and
Autor:
Fred Saad, Amy Kupic, Blair Egerdie, Ronaldo Damião, Lawrence Karsh, Zhishen Ye, Neal D. Shore, Hendrik Van Poppel, Paul Sieber, Bertrand Tombal, Joseph L. Chin, Tomasz Borkowski, Roger Dansey, Francisco Gomez-Veiga, Kurt Miller, Matthew R. Smith, Juan Morote, Carsten Goessl, Teuvo L.J. Tammela, Karim Fizazi, Robert E. Coleman
Summary Background Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed denosumab, a fully human anti-RANKL monoclo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca1119392167ddf5e60918ca1e87956a
https://europepmc.org/articles/PMC3671878/
https://europepmc.org/articles/PMC3671878/